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ABSTRACT
Background: Overuse and misuse of prescription opioids is associated with increased morbidity
and mortality, and places a significant cost burden on health systems.
Objective: To estimate annual state-wide spending for prescription opioids in Rhode Island.
Methods: A cross-sectional study of opioids dispensed from retail pharmacies using data from
the Rhode Island (R.I.) Prescription Drug Monitoring Program (PDMP) was performed. The
study sample consisted of 651,227 opioid prescriptions dispensed to 197,062 patients between
January 1, 2015 to December 31, 2015. The mean, median and total cost of opioid utilization was
estimated using both prescription dispensings and patients as units of analysis. A generalized
linear model with gamma distribution with an identity link function and separately with a log
link function were used to estimate the annual adjusted average prescription opioid cost and to
examine potential predictors of total annual expenditure, respectively.
Results: The estimated annual expenditure for opioid prescriptions in R.I. for 2015 was
$44,271,827. The average and median cost of an opioid prescription were $67.98 (standard
deviation [SD] $210.91) and $21.08 (interquartile range [IQR]: $7.65, $47.51), respectively.
Prescriptions for branded opioid products accounted for $17,380,279.05, which was about 39.3%
of overall spending, although only 6% of all opioids dispensed were for brand-name drugs. On
average, patients aged 45-54 and 55-64 years had overall adjusted spending for opioids that were
1.53 (95% confidence interval [CI]: 1.49, 1.57) and 1.75 (95% CI: 1.71, 1.80) times higher than
patients age 65 years and older, respectively. Per patient Medicaid and Medicare average annual
spending for opioid prescriptions were 1.19 (95% CI: 1.16, 1.22) and 2.01 (95% CI: 1.96, 2.06)
times higher than commercial insurance spending, respectively. Annual opioid prescription
spending was 2.01 (95% CI: 1.98, 2.04) and 1.50 (95% CI: 1.45, 1.55) times higher among
patients who also had at least one benzodiazepine or sympathomimetic stimulant dispensing,
respectively. Average total spending for prescription opioids per patient increased with the
average daily dosage; from 3-fold for patients using 50-90 MME daily to 22-fold for those
receiving 90 or more MME daily compared to those receiving less than 50 MME daily.
Conclusion: This study provides the first estimate of the state-wide direct cost burden of
prescription opioid use using PDMP data and standardized pricing benchmarks. Total annual
cost increased with age up to 65 years, mean daily dose, and concurrent use of benzodiazepines
or stimulants. Commercial insurance bears the majority of the cost of prescription opioid use but
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cost per patient is highest among Medicare beneficiaries. In addition to reducing harms
associated with opioid overuse and misuse, substantial cost savings could be realized by reducing
unnecessary opioid utilization especially among middle aged adults.
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SUMMARY BULLETS
What is Already Known About This Subject:
•

The overuse and misuse of prescription opioids is associated with increased morbidity
and mortality, and places a significant cost burden on health systems. In 2005, White et al
estimated that the total healthcare costs per patient were about 8.5 times higher among
patients with a diagnosis of opioid use disorder compared to similar patients without a
history of opioid use disorder1.

•

The total United States (U.S.) spending for opioid analgesic prescriptions increased
substantially from $2.3 billion in 1999 to $7.4 billion in 2012.

•

The total annual expense for prescription opioid utilization in the outpatient setting in the
U.S. in 2012 has been estimated at approximately $9.0 billion, representing an increase of
120% from 2002.

•

In 2016, the total annual expense for almost 18 million prescription drugs were filled at
retail pharmacies in Rhode Island was about $1.2 billion.

What This Study Adds:
•

Total annual retail expenditure for opioid analgesic prescriptions in Rhode Island for
2015 is estimate at $44,271,827.

•

Total annual per-patient cost for opioid prescriptions is $17.65 higher among adults age
45-54 years, and $28.47 higher among patients of age 55-64 years as compared with
those ages 65 years or older.

•

Commercial insurance bears the majority of the cost of prescription opioid use but cost
per patient is highest among Medicare beneficiaries.

•

More than 10% of patients paid for at least one opioid prescription with cash but cash
payment accounts for only 5.1% of the total annual prescription opioid expenditure.

•

Among patients who also received prescriptions for benzodiazepines, annual cost for
opioid dispensings was approximately twice as such as patients who did not receive
benzodiazepines; while among patients who also received prescriptions for stimulants,
annual cost for opioid dispensings was approximately 50% higher as compared with
patients who did not receive stimulants.
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Introduction
Pain is one of the most common reasons for an outpatient office visit2-4. According to a
2011 Institute of Medicine report, approximately 100 million adults in the United States suffer
from chronic pain each year5. Prescription opioid analgesics are commonly used to treat a variety
of painful conditions ranging from acute injury to palliative care in terminal illness. In 2012,
healthcare providers in the United States issued over 259 million opioid prescriptions6. Higher
rates of opioid prescribing over the past two to three decades may be attributed in part to
historical changes in pain management guidelines, the Joint Commission requirements for
routine pain assessment, promotion by the pharmaceutical industry and changes in
reimbursement and out-of-pocket payment for prescription opioids.7-11
Although the use of prescription opioid analgesics is often clinically necessary, their
addictive and euphoric properties render them liable to misuse and often lead to opioid use
disorders (OUDs). In recent years, deaths from drug overdose have increased dramatically,
exceeding the number of deaths from motor vehicle accidents to become the leading cause of
accidental death in the United States6,12-14. In 2015 alone, drug overdose was responsible for
52,404 deaths, with 33,091 (63.2%) associated with an opioid. More than 60% of opioids
involved in drug overdose deaths are prescription opioids15,16. Benzodiazepines and opioids are
often prescribed together with the potential risk of respiratory depression and overdose death17-19.
The Food and Drug Administration recently issued a boxed warning limiting the concurrent use
of opioids and benzodiazepines or other central nervous system depressants adding to recent
changes in opioid prescribing guidelines20-22.
Currently all states legislatures, with the exception of Missouri, have implemented a
version of a state-run Prescription Drug Monitoring Program (PDMP) designed to identify and
track the prescribing and dispensing of controlled substances, including prescription opioids
dispensed from retail pharmacies. These PDMP aim to alert prescribers of controlled substances
issued by other practitioners, and to promote appropriate prescribing practices by making opioid
medication history accessible to prescribers and pharmacists at the point of care delivery.23 In
most states, including Rhode Island, prescription drugs that are classified as Schedule II, III and
IV, and opioid medications within Schedule V on the Drug Enforcement Administration’s
(DEA) five-tiered schedule are monitored. Drugs are assigned to one of these categories by the
DEA based on their medicinal value and the potential for abuse and diversion.
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While significant attention has been directed towards the health consequences of opioid
prescribing, little has been published on the associated health care costs15,24-26. The annual
societal cost of pain in terms of medical care and lost productivity in the U.S. has been estimated
at $635 billion, in 2010 dollars5. White et al (2005) estimated that the total healthcare costs per
patient varied from $15,884 to $18,388 among patients with an opioid use disorder diagnosis
compared with only $1,830 to $2,210 among a similar group of patients with no documented
history of an opioid use disorder1. Recent publications of cost related to opioid use have
examined trends in expenditures using national Medicare data and Medical Expenditure Panel
Survey (MEPS)24,27. Zhou et al estimated that the total U.S. spending for opioid analgesic
prescriptions increased substantially from $2.3 billion in 1999 to $7.4 billion in 2012,27 while
Stagnitti et al estimated the total expenses for outpatient prescription opioids at $9.0 billion in
2012, an increase of 120% from 200228.
The statewide health system impact of opioid use can be quantified in terms of the direct
cost of prescriptions to payers. To date, no published studies have examined state-level direct
costs associated with prescription opioid dispensings from retail pharmacies, across different age
groups, gender, medication types and source of payment. Data from the R.I. PDMP was used
estimate the distribution of the direct cost of opioid prescriptions dispensed by retail pharmacies
in R.I. during the calendar year 2015. The goal of this analysis was to determine the total annual
expenditure for prescription opioid analgesics in R.I. for 2015 as captured in the PDMP. The
proportions of spending associated with cash payment, and by public and private payers were
determined. Finally, the study evaluated if gender, age group, payment type or use of other
benzodiazepines or stimulants was associated with the total annual prescription opioid cost per
patient. Understanding these factors may help elucidate the extent of opioid use statewide and
provide support for efforts by providers, public health regulators and payers to reduce the misuse
of prescription opioid analgesics.29
Methods
Study Design and Data Source: A cross-sectional study was conducted to examine annual
opioid utilization and spending by patient and by type of opioid medication dispensed using data
from the 2015 R.I. PDMP. These included all DEA Schedule II to IV prescription medications
dispensed by retail pharmacies licensed within the state (A new state law that was signed on June
28, 2016 requires pharmacies to monitor Schedule II to V controlled substances). Pharmacies
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holding a retail license in R.I. are legally required to electronically report all monitored
controlled substances filled within one business day of the prescription being dispensed to the
patient. This includes independent pharmacies, chain pharmacies, food stores, and mass
merchandisers, but not substance abuse treatment programs, in-patient hospital pharmacy
services and correctional facilities. A commercial vendor links multiple prescriptions for each
patient using probabilistic techniques based on the patient’s name, date of birth, and street
address30,31. Similarly, all prescriptions written by each provider and dispensed by the pharmacist
are linked by unique prescriber DEA numbers. The data provided by the R. I. Department of
Health for our study included only de-identified patient, prescriber, and dispensing pharmacy
information. Available information included patient age (in years), gender, a unique prescriber
and dispensing pharmacy identifier, the National Drug Code (NDC), product name, strength,
formulation, and therapeutic class code of each prescription as well as the number of days
supplied, metric quantity dispensed, method of payment and the date the prescription was filled.
The pharmacist estimated “days’ supply” based on the quantity prescribed and the daily dosage.
Patients who were 65 years of age and older and had commercial insurance documented as their
method of payment were reclassified as covered by Medicare, as there was no way to distinguish
individuals who were enrolled in a Medicare Advantage plan from those receiving employerbased insurance. The payment type field was populated by the dispensing pharmacist, and a
payment type of “commercial” was incorrectly assigned for a majority of Medicare-eligible
adults.
Cohort selection: All individuals with at least one prescription dispensing of any Schedule II to
IV controlled substance was first identified. There were 2,058,816 controlled substance
prescriptions dispensed at retail pharmacies in 2015. This includes opioid analgesics,
benzodiazepines, stimulants, skeletal muscles relaxants, and sleep aids. All prescriptions for nonopioid agents were first excluded (Figure 1); buprenorphine-containing products were excluded
as they are typically indicated for substance and OUD treatment; tramadol was also excluded
because it is considered a mixed opioid-like analgesic32,33, and compounded formulations and
bulk containers for which standardized pricing benchmarks were unavailable were excluded.
Opioid medications were classified by drug type using NDCs. The analytic sample consisted of
651,227 opioid prescriptions dispensed to 197,062 patients from retail pharmacies in R.I.
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between January 1, 2015 to December 31, 2015.

The U.S. Census Bureau estimated the

population of Rhode Island to be 1,056,298 in 201534. A prescription dispensing was defined as
any prescription drug filled at a retail pharmacy and sold to a patient or patient’s agent on a
particular day, whether a new or refilled prescription.
To determine the unit price of each opioid prescription, NDCs for opioid dispensings
were first matched with the 2015 R.I. Medicaid Maximum Allowable Cost (MAC) listing as the
default unit price for both brand name and generic products. For sole source (i.e. branded)
products and other NDCs that did not match with the Medicaid MAC listing, pricing data from
the RED BOOK® (Truven Health Analytics, Inc.), which provided the Average Wholesale Price
(AWP) and Federal Upper Limit (FUL) prices during 2015 was used. These costs were assigned
using the lesser of AWP–14% or FUL. The discounting of AWP was determined in consultation
with experts in the field as a conservative estimate of drug costs. Sources of payment reported
included cash (private pay), commercial insurance, Medicare, Medicaid, and others such as
worker’s compensation, Indian Health Service, the Veterans Health Administration, Tricare, and
other federal sources.
We hypothesized that the total annual expenditure for opioid prescriptions was associated
with the use of benzodiazepines or stimulants, use of higher daily doses of opioids, and use of
multiple providers and pharmacies. The study determined if opioid prescription expenditure was
associated with patient age groups, gender or payment type. Use of benzodiazepines or
stimulants were defined as use of one or more prescriptions of either a benzodiazepine or a
stimulant within the study year. The dosage of each prescription opioid dispensed was converted
to its morphine milligram equivalent (MME) per day using NDC-based conversion factors
published by the Centers for Disease Control National Center for Injury Prevention and Control
in June, 201535-38. Finally, a measure of potential health system abuse was defined as patients
who received prescriptions for an opioid from five or more prescribers filled by five or more
pharmacies within the 12 month period (5/5/12 criteria), so-called multiple provider episodes
(MPE) or doctor shopping39.
Statistical Analysis: The mean, median and total costs of opioid utilization were estimated using
both prescription dispensings and patients as units of analysis. All costs were retained in 2015
US dollars. The last prescription received during the study year was used to identify the most
recently used opioid type and and to assign medication type and source of payment when
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patients were used as the unit of analysis. We determined overall annual spending for opioid
medications and further categorized spending by age group (<18, 18-24, 25-34, 35-44, 45-54, 5564, 65+), gender, medication type, and payment type. Annual cost values were non-normally
distributed with a large right skew (skewness = 22.66). Therefore, using patients as the unit of
analysis, a generalized linear model with gamma distribution with an identity link function and
separately with a log link function were used to estimate the annual adjusted average prescription
opioid cost, and to examine potential predictors of total annual expenditure, respectively40,41.
Independent variables included in the model were age group, gender, payment type, mean daily
MME per patient, use of benzodiazepines or stimulants, and MPE. The modified Park test was
used to identify and specify the appropriate distribution of the dependent variable conditional on
the link function. The gamma family was selected, which has a constant coefficient of variation
and assumes that the variance is proportional to the square of the mean41,42. All analyses were
performed with SAS version 9.4 (SAS Institute, Cary, NC) and all statistical tests were two-sided
and performed at the 0.05 significance level. The study was approved by the Institutional Review
Board at the University of Rhode Island.
Results
The study population consisted of 197,062 residents who filled a total of 651,227 opioid
prescriptions in 2015. This represents an estimated 18.7% of residents who received at least one
dispensing for an opioid medication from a retail pharmacy during 2015. Approximately 56% of
patients who filled at least one opioid prescription were female (Table 1). About 23.9% were
aged 65 years and older, and 38.3% were ages 45-64 years. Based on the last opioid prescription
dispensed, most patients were prescribed either hydrocodone or oxycodone (83.1%).
Approximately 58.2% of patients had commercial insurance, 21.9% were covered by Medicare
and almost 10% of patients paid for their prescription using cash. More than 90% of patients
used only one method of payment during the study year. A subgroup analysis of cash payment
for all opioid prescriptions showed that 21,538 patients used cash payment for least one opioid
prescription in 2015. Among them 16,240 (75.40%) patients used only cash payment for all
opioid prescriptions filled at the retail pharmacy while 5,298 (24.60%) patients used two or more
types of insurance payment during the same calendar year (Appendix B).
The total annual retail expenditure for opioid prescriptions in R.I. for 2015 was estimated
at $44,271,827, which corresponds to an average spending of $3.7 million per month. The
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average and median cost of an opioid prescription were $67.98 (SD $210.91) and $21.08 (IQR:
$7.65, $47.51), respectively. Both the number of opioid prescriptions dispensed and per-patient
annual spending increased with age, but appeared to stabilize among patients age 45 or older
(Table 2). The total annual prescription opioid spending for patients age 45-64 years was
estimated to be $26,337,403.49 and this was not only proportionately higher than for patients age
65 and older but also higher than spending for any other age group. Oxycodone and hydrocodone
were the most commonly dispensed opioid prescriptions, accounting for more than 82% of all
prescriptions filled. The total annual expenditure for these two drug types was approximately
$32.5 million, which accounts for 73% of all opioid prescription spending. The average cost of
an oxycodone prescription was approximately $50 more than hydrocodone, reflecting a
dramatically higher cost for extended-release (ER) oxycodone as compared with hydrocodone
products, which were mostly dispensed in generic immediate-release forms. The average and
median costs of a prescription of oxymorphone were $595.72 (SD $512.60) and $439.68 (IQR:
$246.94, $779.81), respectively, making it the most costly opioid prescription type including
brand name and generic products. Branded opioid prescriptions were far more expensive than
their generic counterparts. However, 94% of all opioid prescriptions were for a generic product,
with an average price of $43.90 (SD $116.21) compared to $449.78 (SD $616.97) per brandname prescription. Branded opioid prescriptions accounted for $17,380,279.05 of the yearly
total, which was about 39.3% of overall spending, although only 6% of all opioids dispensed
were for brand-name drugs. Commercial insurance was the most common method of payment
type for opioid prescriptions (51%) followed closely by Medicare (29.4%). Cash payment was
used for 60,548 or 9.3% of all prescription opioids dispensed. We found that on average
Medicare spent $85.31 (95% CI: $84.24, $86.39) per opioid prescription, which is significantly
more than Medicaid and private insurance which spent $52.15 (95% CI: $50.82, $53.48) and
$65.55 (95% CI: $64.83, $66.28) per prescription, respectively. However, commercial insurance
was responsible for 49.3% of the total expenditure while Medicaid and Medicare paid for only
6.1% and 36.9%, respectively. Cash payment represented 5.1% of the annual spending.
Table 3 presents the results of a generalized linear model. Gender, age group, payment
type, mean daily MME per patients, use of benzodiazepines or stimulants, and MPE were all
statistically significant predictors of total annual expenditure. Using a gamma regression model
with an identity link function, patients aged 45-54 and 55-64 years had overall adjusted mean
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spending for opioids that were $17.65 (95% CI: $15.26, $20.04) and $28.47 (95% CI: $26.06,
$30.88) higher, respectively, than patients aged 65 and older. As expected, the youngest patients
had significantly lower adjusted total expenditure per patient as compared with adults over 65
years of age. With regard to the method of payment, overall adjusted mean cost per Medicare
and Medicaid patients were $33.20 (95% CI: $31.05, $35.35) and $0.56 (95% CI: -$0.51, $1.63)
higher, respectively, compared with commercially insured patients, while patients who used cash
payments spent on average $3.80 less than the amount charged to customers with commercial
insurance.
Patients who were dispensed a benzodiazepine (26.5%) or sympathomimetic stimulants
(4.4%) had higher annual spending for opioid medications than those who did not also receive
dispensings for these medications. On average, annual opioid prescription cost was $35.99 (95%
CI: $34.45, $37.54) higher among patients who also received at least one benzodiazepine
dispensing; while annual opioid prescription cost was $8.61 (95% CI: $6.47, $10.76) higher
among patients who also had at least one dispensing for a stimulant medication. As a most
statistically significant predictor of annual opioid expenditure, for patients with MPE, average
annual cost of opioid prescriptions per patient was increased by approximately $863.58 (95% CI:
$689.48, $1037.68) compared to patients who did not meet this criteria. The annual total opioid
spending per patient also increased substantially with the use of higher daily doses of opioids, as
average total cost was more than $337.73 (95% CI: $332.84, $342.62) greater among patients
utilizing on average more than 90 MME daily, as compared with patients receiving on average
less than 50 MME daily.
Using gamma regression model with a log link function (Table 3), there was a 69%
reduction in overall adjusted average cost per patient when comparing those who were age 18
years or younger to those age 65 years and older. Conversely, patients aged 45-54 and 55-64
years had overall adjusted average spending for opioids that were 1.53 (95% CI: 1.49, 1.57) and
1.75 (95% CI: 1.71, 1.80) times higher, respectively, than patients age 65 years and older. Per
patient Medicaid and Medicare average annual spending for opioid prescriptions were 1.19 (95%
CI: 1.16, 1.22) and 2.01 (95% CI: 1.96, 2.06) times higher than commercial insurance spending,
respectively, while average spending per patient using cash payment was 17.4% lower than
charges to commercial payers. Furthermore, patients who were dispensed a benzodiazepine or a
sympathomimetic stimulant had higher annual spending for opioid medications than those who
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were not. On average, annual opioid prescription spending was 2.01 (95% CI: 1.98, 2.04) and
1.50 (95% CI: 1.45, 1.55) times higher among patients who also had at least one benzodiazepine
or stimulant dispensing, respectively. Average total spending for prescription opioids per patient
increased with the average daily dosage; from 3-fold for patients using 50-90 MME daily to 22fold for those receiving 90 or more MME daily compared to those receiving less than 50 MME
daily. Finally, patients with MPEs had mean adjusted annual opioid spending that was 4.34 (95%
CI: 3.75, 5.02) times higher than patients who did not use multiple prescribers and pharmacies .
Discussion
A total of 197,062 patients - or an estimated 18.7% of the state’s population received at
least one dispensing for an opioid medication from a retail pharmacy in Rhode Island during
2015. The total number of opioid prescriptions filled was 651,227 which corresponds to an
average of 3.3 prescriptions per resident per year; or an estimated opioid prescribing rate of
61.65 prescriptions per 100 residents, which is comparable to rates estimated for other
neighboring states and the rest of the country39,43.
The direct cost burden of prescription opioids was determined using data from a
statewide PDMP which provides the advantage of capturing controlled substance dispensings at
the level of the pharmacy and encompasses dispensings for all providers and payment types,
including cash. Thus, estimates from this study provide results that are more generalizable to the
overall population, as compared with analyses of a particular payer’s pharmacy claims. As
PDMP programs do not include drug pricing information, this information was assimilated from
other sources, providing what we believe is the first estimate of the direct annual cost burden of
prescription opioid use, estimated at $44,271,827.00 for a population of approximately 1 million,
in 2015 dollars. This represents about 3.7% of total prescription drug sale at retail pharmacies in
RI for 2016 according to estimates report published recently by the Kaiser Family Foundation 44.
According to the study based on IMS Health national prescription audit data, the total
expenditure for all 18 million prescription drugs dispensed at retail pharmacies in R.I. in 2016
was estimated at $1.2 billion. The estimate from this study does not include dispensings for
tramadol, compounded products, or opioids dispensed in substance and OUD treatment centers,
during in-patient hospital care or in state correctional facilities.
The cost associated with prescription opioid use is determined in part by both the
intensity of use (i.e. number of dispensings and daily dosage) and the opioid product prescribed.
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Patients aged 45-64 years accounted for 47.14% of all opioid prescriptions dispensed, and
59.49% of the total expenditure. While mean costs were highest for prescriptions for
oxymorphone ($595.72), levorphanol ($560.80) and tapentadol ($492.86), dispensings for these
medications accounted for only 3.7% of total overall annual cost. More than half (53.8%) of the
annual cost of opioid medications for 2015 was associated with oxycodone dispensings, most of
which can be attributed to higher cost ER formulations. Extended release formulations accounted
for almost 50% of the total annual expenditure even though they represent only 11% of all
prescriptions. Efforts to address the cost burden of opioid overuse might target this middle-aged
subgroup, with focus on reducing the long term use of opioids, many of which are prescribed as
higher cost ER formulations. Evidence for the use of opioids for chronic pain is very limited
amidst mounting evidence of serious dose-dependent harm45. Both decreasing the unnecessary
use of oxycodone ER for treatment of acute pain, and the availability of a less costly generic
formulation of this medication would have a dramatic effect on opioid expenditure, potentially
yielding significant savings to the health care system.
Doctor shopping behavior and the use of cash for prescription opioid payment especially
when the patient also has other types of insurance coverage may indicate prescription opioid
misuse46. About 21,538 (10.93%) patients paid at least one opioid prescription with cash during
the calendar year and approximately 25% of these patients used at least one other type of
insurance to pay for opioid prescriptions during the same year. The overall adjusted average
prescription opioid spending for the 409 patients that met the 5/5/12 criteria was dramatically
greater than patients not meeting this criteria ($64.17 vs $927.76, p < 0.001). However, higher
costs associated with potential doctor shopping or use of benzodiazepines or stimulants may be
an indication of poorly managed co-morbid chronic condition resulting from lack of a usual
source of care. Other valid reasons for a patient having multiple providers might include a
change in the primary care provider, a different provider covering the patient’s usual prescriber,
having multiple specialists, and visits to a dentists or the emergency room47. It is envisioned that
the overutilization of prescribers and pharmacies will decrease with increasing public awareness
and implementation of regulations requiring providers to review the PDMP prior to issuing a
prescription for an opioid medication. However, most PDMPs are not currently integrated with
electronic medical records making access to this information time consuming and often
infeasible.
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The finding in this study that nearly 1 in 5 state residents received at least one opioid
prescription during 2015 indicates that opioids are commonly prescribed within the state, and
suggests that a proportion of opioid prescribing may be clinically unnecessary. Levy et al have
reported that opioids are the most commonly prescribed analgesics in the United States48. This
analysis did not examine the clinical indications for which these opioid prescriptions were
dispensed, and thus could not quantify the extent and cost of inappropriate opioid prescribing.
Liu et al found that up to 40% of Medicaid patients receiving an opioid prescription had at least
one marker of inappropriate prescribing such as overlapping opioid prescriptions, overlapping
opioid and benzodiazepine prescriptions, initiation of therapy with a long-acting opioid, use
long-acting opioids for acute pain, or high daily doses more than 90 MME26. The U.S. Centers
for Disease Control and Prevention recently published guidelines for prescribing opioids for
chronic pain in the absence of cancer, palliative or terminal care.20 The guidelines recommend
the use of non-opioids as first line therapy for chronic pain, using opioid analgesics only when
the benefits of such therapy are likely to outweigh the risks, and prescribing the lowest effective
dosage for the shortest number of days, when needed. Many insurers have introduced new
policies to reduce inappropriate opioid prescribing such as drug utilization review, prior
authorization, quantity limitations, and pharmacy management review programs 49,50. Trends in
opioid prescribing should continue to be monitored as a measure of effectiveness of current
public health interventions and narcotic stewardship programs, towards determining if the
frequency and cost burden of opioid use is diminishing.
Limitations: The PDMP database does not include information describing health
conditions or patient diagnoses, laboratory tests, clinician specialty, use of non-controlled
prescription medications, or any other indicators of health care utilization. Since the analysis
could not determine whether an opioid prescription was appropriate, we cannot quantify the cost
of inappropriate opioid prescribing, thus limiting the application of these results to improve
prescribing practices. The total cost estimate does not represent the total cost burden as we could
not estimate the cost of adverse effects or account for opioid prescriptions not filled in retail
pharmacies. Furthermore, estimates from this study are a general approximation because payer
reimbursement rates may vary from the methods we applied in our analysis to some degree. The
patient’s state of residence could not be determined. However, the number of patients from
neighboring states who received opioid prescriptions from R.I. pharmacies is likely to be offset
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by the number of R.I. residents who filled opioid prescriptions at pharmacies in neighboring
states. Additionally, the payment type variable was poorly reliable with regard to capturing
Medicare as a payment source. An undetermined number of older adults were misclassified as
having commercial insurance, and while we attempted to address this issue by reassigning these
patients as covered by a Medicare drug plan, our ability to make inferences regarding opioid
expenditure by Medicare Advantage plans in particular is nevertheless limited. Finally, we
recognize that the direct cost of prescriptions is merely one component driving health system
expenses associated with pain management and opioid use in particular. Consideration of other
treatment modalities, medical care, and humanistic outcomes should be included in health
economic analyses assessing opioid use as facet of pain management.
Conclusion
This study provides the first estimate of the state-wide direct cost burden of prescription
opioid use using PDMP data and standardized pricing benchmarks. Total annual cost increased
with age up to 65 years, mean daily dose, and concurrent use of benzodiazepines or stimulants.
Commercial insurance bore the majority of the cost of prescription opioid use but cost per patient
was highest among Medicare beneficiaries. Almost 11% of patients used cash payment at least
once during the calendar and cash payment accounted for about 5.1% of the total annual
prescription opioid expenditure. This analysis suggests that substantial cost savings could result
from increased use of generic formulations of commonly prescribed opioid products. Greater
savings and improved patient health outcomes could be realized by reducing overall opioid
utilization, especially among middle age individuals.
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Figure 1. Sample Identification Flowchart

Schedule II-IV prescriptions dispensed by
Rhode Island Retail Pharmacies in 2015
(N=2,058,816)
Non-opioids (N=1,249,525)

Benzodiazepines (N=637,471)
Stimulants (N=348,640)
Others (N=263,414)

Opioid-like agents (N=809,291)
opioids

Buprenorphine-containing products (N=44,850)

Opioids prescribed for pain (N=764,441)
Tramadol (N=112,892)

True opioids (N=651,459)

Compounded and bulk products (N=232)

Analytic sample dispensing (N=651,227)

Unique patients identified (N=197,062)
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Table 1 Characteristics of Individuals Who Filled at Least one Opioid Prescription at a
Retail Pharmacy in R.I. in 2015 (N = 197,062)
Characteristica

n (% of N)

Genderb

110,001 (55.82)
87,043 (44.17)

Female
Male
Age Group, Years
less than 18
18-24
25-34
35-44
45-54
55-64
greater than 65
Payment Method
Commercial Insurance
Medicare
Cash
Medicaid
Otherc
Most Recent Opioid Dispensed
Hydrocodone
Oxycodone
Codeine-based
Morphine
Hydromorphone
Fentanyl
Methadone
Tapentadol
Oxymorphone
Meperidine
Pentazocine
Butorphanol
Levorphanol
Otherse
Mean daily MME per patientf
≤ 50
50-90
90+
Benzodiazepine use
No
Yes
Stimulant use
No
Yes
5/5/12 criteria
Not met
met

5,995
15,327
27,302
27,738
37,155
38,372
45,173

(3.04)
(7.78)
(13.85)
(14.08)
(18.85)
(19.47)
(22.92)

114,654 (58.18)
43,213 (21.93)
19,476 (9.88)
15,767 (8.00)
3,952 (2.01)
90,151
73,622
18,409
6,894
3,698
1,450
650
192
146
64
50
35
1
1,700

(45.75)
(37.36)
(9.34)
(3.50)
(1.88)
(0.74)
(0.33)
(0.10)
(0.07)
(0.03)
(0.03)
(0.02)
(0.00)
(0.86)

153,085 (77.68)
32,081 (16.28)
8,536 (4.33)
144,899 (73.53)
52,163 (26.47)
188,343 (95.58)
8,719 (4.42)
196,653 (99.79)
409
(0.21)

a

Gender, payment method, medication type and mean daily MME classified according to data captured in the last prescription
dispensed in 2015.
b
Gender was not reported for 18 patients (0.01%).
d
Includes worker’s compensation, Indian Health Services, the Veterans Health Administration, Tricare, other federal sources.
e
Primarily opioid-containing cough products (see Appendix A)
f
MME=Morphine milligram equivalent; unable to determine MME for 3,360 (1.71%) of patients
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Table 2. Opioid Prescriptions Dispensed in by R.I. Retail Pharmacies in 2015
Characteristic

Overall
Age group, years
less than 18
18-24
25-34
35-44
45-54
55-64
greater than 65
Medication type
Butorphanol
Codeine-based
Fentanyl
Hydrocodone
Hydromorphone
Levorphanol
Meperidine
Methadone
Morphine
Oxycodone
Oxymorphone
Pentazocine
Tapentadol
Othersa
MME dailyb
≤ 50
50-90
90+
Generic or Brand name
Generic
Brand name
Duration of action
Short-acting
Long-acting
Payment typec
Commercial
Medicare
Medicaid
Private pay
Otherd

Number of
Prescriptions (%)

Prescription Cost ($)

% Total
Cost

Mean (SD)
67.98 (210.91)

Median
21.08

Total
44,271,827.00

(1.21)
(3.50)
(8.84)
(12.91)
(22.21)
(24.93)
(26.40)

20.78 (41.63)
15.45 (43.29)
34.55 (145.80)
61.08 (223.88)
81.01 (247.86)
90.07 (251.01)
59.87 (154.39)

8.54
7.02
9.36
16.47
22.95
25.32
22.95

163,902.33
352,063.77
1,990,258.63
5,135,736.95
11,714,458.06
14,622,945.43
10,292,461.84

0.37
0.80
4.50
11.60
26.46
33.03
23.25

355 (0.05)
37,100 (5.70)
15,169 (2.33)
253,850 (38.98)
9,717 (1.47)
9 (0.00)
261 (0.04)
7,156 (1.10)
35,462 (5.45)
281,225 (43.18)
1,810 (0.28)
341 (0.05)
1,103 (0.17)
7,669 (1.18)

163.90 (109.88)
6.86 (6.99)
204.43 (552.01)
34.15 (54.21)
209.70 (554.09)
560.08 (907.64)
29.20 (24.95)
41.82 (32.23)
108.67 (267.76)
84.69 (235.80)
595.72 (512.60)
173.27 (178.45)
492.86 (293.16)
63.64 (99.66)

163.59
4.43
126.66
21.42
18.23
103.12
19.13
29.70
40.22
21.18
439.68
178.75
421.98
38.16

58,184.34
254,557.96
3,101,069.73
8,668,532.13
2,037,677.97
5,040.76
7,620.44
299,254.81
3,853,808.20
23,817,051.40
1,078,255.85
59,084.86
543,626.74
488,061.81

0.13
0.57
7.00
19.58
4.60
0.01
0.02
0.68
8.70
53.80
2.44
0.13
1.23
1.10

430,519 (66.11)
135,105 (20.75)
81,145 (12.46)

30.28 (53.62)
70.26 (137.46)
265.42 (513.27)

14.39
28.51
87.73

13,034,889.82
9,492,612.15
21,537,624.36

29.44
21.44
48.65

612,585 (94.07)
38,642 (5.93)

43.90 (116.21)
449.78 (616.97)

19.13
279.43

26,891,547.96
17,380,279.05

60.74
39.26

579,849 (89.04)
71,378 (10.96)

38.27 (128.72)
309.36 (453.68)

16.47
136.26

22,190,457.00
22,081,370.01

50.12
49.88

332,088 (50.99)
191,554 (29.41)
51,490 (7.91)
60,548 (9.3)
15,546 (2.39)

65.55
85.31
52.15
37.18
78.72

19.00
28.08
15.13
14.39
20.11

21,769,832.09
16,341,749.85
2,685,118.58
2,251,262.97
1,223,849.24

49.17
36.91
6.07
5.09
2.76

651,227
7,889
22,794
57,597
84,085
144,608
162,352
171,902

(213.46)
(240.12)
(154.24)
(97.84)
(234.92)

100.00

a

Primarily opioid-containing cough products (see Appendix A)

b

MME=Morphine milligram equivalent; unable to determine MME for 1.71% of observations
If age ≥ 65 and Commercial ins. then payment type was reclassified as Medicare; Method of payment was missing for 1 prescription.
Includes worker’s compensation, Indian Nation, the Veterans Health Administration, Tricare, other federal sources.

c

d
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Table 3: Adjusted per-Patient Total Annual Prescription Opioid Costs by Patient Demographic and
Utilization Characteristics (N=197,062)

Independent variable
Intercept
Age group (years)
65 +
less than 18
18-24
25-34
35-44
45-54
55-64
Gender
Female
Male
Payment typec
Commercial
Medicaid
Medicare
Private Pay
Otherd
Mean daily MME per
patient
≤50
50-90
>90
Benzodiazepine usee
No
Yes (n = 52,163)
Stimulant usef
No
Yes (n = 8,719)
5/5/12 Criteriaf
Not Met
Met (n = 409)

Mean cost per patient ($)a
[95% CI]

(62.25, 66.10)

Adjusted
β-coeffb
3.8415

SE
0.0136

95% Conf. Interval
(3.8149, 3.8680)

Reference
-45.89 (-48.09, -43.68)
-50.22 (-52.13, -48.31)
-42.10 (-44.04, -40.17)
-11.89 (-14.20, -9.59)
17.65 (15.26, 20.04)
28.47 (26.06, 30.88)

-1.1680
-1.2910
-0.7492
-0.0415
0.4257
0.5621

0.0243
0.0173
0.0150
0.0149
0.0139
0.0137

(-1.2157, -1.1204)
(-1.3250, -1.2571)
(-0.7786, -0.7198)
(-0.0706, -0.0124)
(0.3985, 0.4530)
(0.5353, 0.5888)

Reference
5.14
(4.44, 5.84)

0.1364

0.0070

(0.1228, 0.1501)

Reference
0.56 (-0.51, 1.63)
33.20 (31.05, 35.35)
-3.80 (-4.69, -2.91)
9.16 (5.17, 13.15)

0.1733
0.6971
-0.1917
0.2988

0.0129
0.0127
0.0129
0.0250

(0.1481, 0.1986)
(0.6722, 0.7220)
(-0.2170,-0.1663)
(0.2498, 0.3479)

Reference
97.91 (95.14, 100.68)
337.73 (332.84 , 342.62)

1.0756
3.1124

0.0092
0.0168

(1.0575, 1.0938)
(3.0795, 3.1453)

Reference
35.99 (34.45, 37.54)

0.6980

0.0079

(0.6825, 0.7135)

Reference
8.61 (6.47, 10.76)

0.4062

0.0167

(0.3735,0.4390)

Reference
863.58 (689.48, 037.68)

1.4672

0.0741

(1.3220, 1.6125)

64.17

a

Mean cost per patient estimated using the identity link function;
Coefficients of gamma regression and standard errors estimated using the log link function;
If age ≥ 65 and Commercial Ins. then payment method was reclassified as Medicare;
d
Includes worker’s compensation, Indian Nation, the Veterans Health Administration, Tricare, other federal sources;
e,f
Use of other benzodiazepines and stimulants defined as one of more prescriptions in a 12 month period.
f
5/5/12/ Criteria: Opioid prescriptions from at least 5 different pharmacies and 5 different prescribers during the 12 month period.
b
c
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Appendix A.
List of medications classified as “other” under opioid medication types in Table 1,2 &3.
Medications
Acetaminophen with codeine
Anhydrous morphine (Paregoric®)
Brompheniramine, codeine with phenylephrine
Butalbital, acetaminophen and caffeine with codeine phosphate
Butalbital, aspirin, caffeine with codeine phosphate
Carisoprodol, aspirin, and codeine phosphate
Codeine sulfate
Hydrocodone bitartrate with homatropine methylbromide
Hydrocodone with chlorpheniramine
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Appendix B.
Use of Other Types of Insurance among 21,538 Patients Making Cash Payments for Opioid
Prescriptions at Retail Pharmacies in R.I. in 2015

Insurance types used
Cash payment for all opioid dispensings
Cash plus only one other type of insurance
Cash plus 2 other types of insurance
Cash plus 3 other types of insurance

Number of patients (%)
16,240 (75.40)
4,835 (22.45)
447 (2.08)
16 (0.07)
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